BC
SRPT icon

Broadfin Capital’s Sarepta Therapeutics SRPT Stock Holding History

Broadfin Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-151,655
Closed -$3.64M – 77
2014
Q1 		$3.64M Sell
151,655
-575,000
-79% -$14.7M 0.35% 63
2013
Q4 		$14.8M Buy
+726,655
New +$21.6M 1.95% 18

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Broadfin Capital's SRPT Position: Q2 2014 in Review

Broadfin Capital sold out of Sarepta Therapeutics (SRPT) in Q2 2014, closing a stake of 151,655 shares — an estimated $3.64M sold.

Broadfin Capital first reported a position in SRPT in Q4 2013 and held it in 2 quarters. The position peaked at $14.8M in Q4 2013. 128 funds tracked by Wall St. Rank hold SRPT as of Q2 2014.

  • Broadfin Capital reported no remaining Sarepta Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Broadfin Capital sold 151,655 Sarepta Therapeutics shares in Q2 2014, an estimated $3.64M.
  • Broadfin Capital first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 2 quarters.
  • Broadfin Capital's Sarepta Therapeutics position peaked at $14.8M in Q4 2013.
  • 128 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2014.

Based on Broadfin Capital's 13F filing for Q2 2014, filed 14 Aug 2014.